SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

Market sentiment for the S&P 500 is heavily focused on the upcoming Federal Reserve interest rate decision, with traders debating whether persistent inflation and geopolitical tensions in the Middle East will force a hawkish stance. The community is actively discussing the potential for a "nothing burger" outcome versus a volatile market reaction as participants weigh the impact of higher oil prices and stagnant rate projections on the broader bull trend.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing intense trading activity as retail and institutional investors debate whether the stock's massive year-to-date rally is justified by surging AI-driven memory demand or is an unsustainable bubble prone to a sharp reversal. The community is heavily focused on upcoming sector catalysts and Micron's earnings report, with bullish traders betting on continued supply shortages while bearish speculators remain active in calling for a significant pullback.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing significant momentum as it heads into its quarterly earnings report, with investors focused on the company's critical role in the AI memory supply chain and its capacity to meet demand for HBM chips. While some community members anticipate a massive breakout or a stock split, others are closely watching for potential profit-taking and volatility given the stock's substantial run-up and high implied move expectations.

SSgA Active Trust - State Street SPDR Dow Jones Industrial Average ETF Trust

The SPDR Dow Jones Industrial Average ETF (DIA) is trending as investors grapple with heightened volatility driven by the escalating conflict in Iran and its subsequent impact on global energy supplies. Market sentiment remains fragile as participants closely monitor potential inflationary pressures, shifting geopolitical risks in the Strait of Hormuz, and the Federal Reserves upcoming policy decisions regarding interest rates.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is experiencing intense volatility as market participants fixate on Federal Reserve Chair Jerome Powell's comments regarding inflation, energy price shocks, and the ongoing uncertainty surrounding Middle East conflicts. Traders are actively debating whether these macroeconomic headwinds will lead to a broader market correction or if persistent algorithmic support will continue to prop up the index, with much of the current discussion centered on the lack of clarity regarding future interest rate cuts.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is experiencing significant upward momentum driven by aggressive institutional buying and speculative interest in the edge computing and AI sector. The community remains deeply divided, with bulls pointing to the stock's resilience and growth potential, while skeptics warn of market manipulation, heavy insider selling, and a lack of fundamental profitability.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate Inc. is experiencing intense volatility and heavy trading volume as investors debate the impact of recent manufacturing-related inquiries from the FDA ahead of their upcoming PDUFA date. While some market participants are liquidating positions due to concerns over potential delays, a vocal segment of the community remains bullish, viewing the pullback as a buying opportunity and maintaining confidence in the company's long-term commercialization thesis and intellectual property portfolio.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is experiencing extreme volatility and heavy retail interest following an explosive IPO, with the community actively debating whether the company's defense-focused drone software and battlefield-proven narrative justify its massive valuation relative to its current financials. Traders are closely watching for potential breakouts past psychological resistance levels, with many speculating on the potential for institutional contracts and multi-day momentum similar to past high-hype market runners.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is experiencing high volatility as investors react to a combination of strong earnings, recent insider buying, and significant institutional interest from funds like Cathie Wood's ARK. The community is actively debating the stock's future, weighing potential short-squeeze dynamics against ongoing concerns about competitive pressures and software sector valuation.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is experiencing high volatility as the market reacts to shifting geopolitical tensions and the upcoming quarterly earnings report. The community is heavily focused on the company's progress with its USV maritime technology and the expectation of future government defense contracts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Barclays said it believes a third hyperscaler contract is "imminent" for Solaris.</li><li>Solaris on Tuesday announced it has closed two transactions that will add approximately 900 MW of new, natural gas-fueled turbine capacity between 2026 and 2029.</li><li>Solaris paid approximately $240 million in cash and issued approximately 4 million Solaris Class A shares.</li></ul>Solaris Energy (<a href="https://stocktwits.com/symbol/SEI">SEI</a>) shares hit a&nbsp;one-year high on Tuesday after a Barclays analyst raised the stock's price target.At the time of writing,&nbsp;SEI shares were trading nearly 15% up, at around $65.38.Barclays raised its price target on Solaris Energy to $74 from $63 and maintained an ‘Overweight’ rating on the shares, per TheFly.<h2 class="st-heading-2">Analyst Rationale</h2>Barclays analyst J. David Anderson, in a research note to investors, said that the addition of 900&nbsp;megawatts of new, natural gas-fueled turbine capacity between 2026 and 2029 accelerates Solaris' growth trajectory.&nbsp;Barclays said it believes a third hyperscaler contract is "imminent" for Solaris.<h2 class="st-heading-2">Capacity Expansion</h2>Solaris on Tuesday announced it has closed two transactions that will add approximately 900 MW of new, natural gas-fueled turbine capacity between 2026 and 2029.Solaris has closed the acquisition of Genco Power Solutions, a distributed power generation company that will add 400 MW of incremental power generation capacity to Solaris between 2026 and 2028, inclusive of approximately 100 MW of currently operated and contracted capacity.&nbsp;Earlier in the week, Solaris also purchased 30 turbine delivery slots from a private party, which will provide approximately 500 MW of incremental power generation capacity between early 2027 and 2029.For both transactions, Solaris paid approximately $240 million of cash, issued approximately&nbsp;four million Solaris Class A shares (valued at approximately $215 million), and assumed approximately $165 million of indebtedness, it said in a statement.The company will now operate approximately 3,100 MW of total power generation capacity by the end of 2029. The company has also closed a new $300 million credit facility to support ongoing growth.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around SEI stock jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours. Message volume also jumped from ‘low’ to ‘high’ over the same period.Shares in the company have risen 39.5% so far in 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Barclays raised its price target on Solaris Energy to $74 from $63, and maintained an ‘Overweight’ rating on the shares, per TheFly.

Why Did Solaris Energy Stock Hit A 1-Year High Today?

Barclays raised its price target on Solaris Energy to $74 from $63 and maintained an ‘Overweight’ rating on the shares, per TheFly.

Equity

Barclays raised its price target on Solaris Energy to $74 from $63 and maintained an ‘Overweight’ rating on the shares, per TheFly.


<ul class="summary-bullets"><li>Greenwich noted that despite the absence of a placebo arm, GLSI-100 showed an annual recurrence rate below 1%, compared with about 4% in the KATHERINE trial of Kadcyla over a similar timeframe.</li><li>The company also stated that the Phase III trial results are trending in line with those from the Phase IIb trial.</li><li>Greenwich reported a reduction of up to 80% in breast cancer recurrences, while other approved products showed a reduction of 20% to 25%, the company said.</li></ul>Greenwich LifeSciences Inc. (GLSI) shares gained more than 13% in Tuesday’s pre-market trade after the company announced that its immunotherapy trial has shown a continued reduction in the rate of recurrence of breast cancer.Greenwich LifeSciences said its 250-patient Phase III breast cancer immunotherapy trial, FLAMINGO-01, showed an annual recurrence rate below 1%.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/GLSI">Greenwich LifeSciences</a> trended in the ‘extremely bullish’ territory with message volumes at ‘extremely high’ levels. GLSI was the top trending ticker on the platform at the time of writing.<h2 class="st-heading-2">Results Show About 70-80% Reduction In Recurrence Rate, Says Greenwich</h2>Greenwich noted that despite the absence of a placebo arm, GLSI-100 showed an annual recurrence rate below 1%, compared with about 4% in the KATHERINE trial of Kadcyla over a similar timeframe.The company also stated that the results of the Phase III trial are trending in line with those from the Phase IIb results. Greenwich reported a reduction of up to 80% in breast cancer recurrences, while other approved products showed a reduction of 20% to 25%, the company said.However, Greenwich stated that these Phase III trial results are still preliminary and that the final analysis may differ.The Phase III FLAMINGO-01 trial is designed to evaluate the safety and efficacy of GLSI-100 in HER2-positive breast cancer patients with residual disease or high-risk pathological complete response who have completed neoadjuvant and adjuvant trastuzumab-based therapy.<h2 class="st-heading-2">What Does Greenwich LifeSciences Do?</h2>Greenwich LifeSciences is a clinical-stage biopharmaceutical company based out of Stafford, Texas. It is currently focused on the development of GP2, which is an immunotherapy to prevent breast cancer recurrence in patients who have previously undergone surgery.<a href="https://stocktwits.com/symbol/GLSI">GLSI stock</a> is up 34% year-to-date and 134% over the past 12 months. The iShares Russell 2000 Growth ETF (IWO) is up 22% over the past 12 months, while the iShares Micro-Cap ETF (IWC) is up 40%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-says-fed-chair-powell-should-cut-rates-right-now/cZ3PPPaRIfw">Trump Says Fed Chair Powell Should Cut Rates Right Now</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is GLSI Stock Rising Today?

Greenwich LifeSciences said its Phase III breast cancer immunotherapy trial, involving 250 patients, showed a recurrence rate of under 1% per year.

<ul class="summary-bullets"><li>The company said the errors were identified in the consolidated financial statements for the year ended&nbsp;Dec.&nbsp;31, 2024 as well as out-of-period errors for all three quarters of 2025.</li><li>The majority of these errors relate to accounting for revenue, software development costs, and share-based payments.&nbsp;</li><li>TBRG said that the above-mentioned errors did not result in a material misstatement of its previously issued financial statements.</li></ul>TruBridge&nbsp;Inc.&nbsp;(TBRG), a leading provider of healthcare technology solutions for rural and community hospitals, announced on Monday&nbsp;that it has postponed its fourth-quarter (Q4) and year-end 2025 earnings release and conference call.TruBridge said that it requires additional time for the completion of its year-end audit procedures, and was therefore delaying its results previously scheduled for March 16, 2026.The company will issue a separate announcement confirming the date of the release of fourth quarter and year-end 2025 financial results,&nbsp;it said.&nbsp;Shares of the company declined more than 5% after the announcement.&nbsp;<h2 class="st-heading-2">Errors In Accounting</h2>TruBridge said that while conducting final procedures with the preparation of its financial statements for the fiscal year ended&nbsp;Dec. 31, 2025, errors were identified in the consolidated financial statements for the year ended&nbsp;Dec.&nbsp;31, 2024 as well as out-of-period errors in the condensed financial statements for the quarters ended March 31, June 30, and&nbsp;Sept. 30, 2025.The majority of these errors relate to accounting for revenue, software development costs, and share-based payments.&nbsp;TBRG said that the above-mentioned errors did not result in a material misstatement of its previously issued financial statements, and the errors are non-cash in nature, and do not impact company’s operations or liquidity.&nbsp;TruBridge expects to file the 2025 Form 10-K within the 15-day extension period granted by the&nbsp;U.S. Securities and Exchange Commission (SEC), as well as issue its&nbsp;Q4 and year-end 2025 financial results and hold its rescheduled earnings call by March 31, 2026.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around TBRG&nbsp;stock trended in ‘neutral territory’ amid ‘high’ message volume.&nbsp;Shares in the company have fallen 25% so far in 2026.&nbsp;

Shares of TruBridge have fallen 25% so far in 2026. 

Why Has TruBridge Delayed Its Planned Q4 Results?

TruBridge said that it requires additional time for the completion of its year-end audit procedures.

<ul class="summary-bullets"><li>The company swung to profit in Q4 and reported earnings per share of $0.05 versus year-ago loss per share of $0.22.</li><li>Adjusted operating expenses for the fourth quarter of 2025 were $6.5 million compared to $11.9 million for the fourth quarter of 2024.</li><li>On Stocktwits, retail sentiment around DMRC&nbsp;stock trended in ‘extremely bullish’ territory amid ‘high’ message volume.&nbsp;</li></ul>DigiMarc (DMRC) shares rallied 7% during extended hours of trading after it reported a&nbsp;higher-than-expected&nbsp;fourth-quarter (Q4) revenue on Wednesday.&nbsp;DMRC’s total revenue for Q4 2025 was $8.9 million compared to $8.7 million for the fourth quarter of 2024. Analysts on average expected $8.2 million in revenue, as per data from&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://fiscal.ai">Fiscal.ai</a>.&nbsp;<h2 class="st-heading-2">Q4 Snapshot</h2>DigiMarc’s subscription revenue for Q4 2025 came at $5.3 million compared to $5.0 million for the fourth quarter of 2024. The increase reflects $1.4 million of patent license fees earned during the quarter and higher subscription revenue from new and existing commercial contracts, partially offset by a $1.4 million decrease relating to the expiration of two previously disclosed commercial contracts in 2025,&nbsp;the company said.The company's adjusted net income for Q4 2025 was $1.0 million or $0.05 per diluted share compared to adjusted net loss of $4.6 million or $0.22 per diluted share for the fourth quarter of 2024.“Digimarc is capitalizing on the convergence of key trends driving increased demand for our solutions, positioning ourselves to benefit from - not be the casualty of - the relentless advance of AI," said Riley McCormack, Digimarc CEO. "In Q4 2025, we achieved both positive non-GAAP net income and positive free cash flow. Looking ahead to 2026, we expect to generate significant ARR growth."<h2 class="st-heading-2">Expenses Come Down</h2>Operating expenses for the quarter were $10.0 million, compared to $14.4 million for Q4 2024.&nbsp;The decrease was led by lower cash compensation costs of $4.4 million, largely due to lower headcount, and lower professional services costs of $0.6 million, partially offset by higher stock compensation costs of $0.7 million.&nbsp;Adjusted operating expenses for the quarter were $6.5 million compared to $11.9 million for Q4 2024.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around DMRC&nbsp;stock trended in ‘extremely bullish’ territory amid ‘high’ message volume.&nbsp;Shares in the company have fallen 9.4% so far in 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.

On Stocktwits, retail sentiment around DMRC stock trended in ‘extremely bullish’ territory amid ‘high’ message volume. 

DigiMarc Stock Rallies After Hours On Q4 Revenue Beat

DMRC’s total revenue for the fourth quarter of 2025 was $8.9 million compared to $8.7 million for the fourth quarter of 2024.

<ul class="summary-bullets"><li>The rise in revenue was helped by strong growth in the software and professional services segments.</li><li>Blend Labs’ adjusted diluted net income per share was break-even ($0.00) in both the fourth quarter of 2025 and the same period last year.</li><li>The company said it expects first quarter revenue for 2026 in the range of $28.5 million to $30 million, which was below Wall Street expectations of $31.5 million.&nbsp;</li></ul>Blend Labs shares rallied nearly 9% in extended hours of trading on Tuesday after it posted an upbeat fourth quarter result that cheered investors.The company posted fourth quarter revenue of $32.4 million, an increase of 7% compared to the fourth quarter of 2024.&nbsp; Analysts on average had expected the revenue of $31.78 million, as per data from fiscal.ai.The rise in revenue was helped by strong growth in the software and professional services segment. Software platform revenue was $30.3 million, up 10% year-over-year, and Professional services revenue was $2.1 million compared to $2.5 million in the fourth quarter of 2024.<h2 class="st-heading-2">More Details</h2>Blend Labs’ adjusted diluted net income from continuing operations attributable to common stockholders per share was break-even ($0.00) in both the fourth quarter of 2025 and the same period last year.The company repurchased 5.1 million shares in the fourth quarter for more than $15 million, bringing the year-to-date total to $25 million.<h2 class="st-heading-2">Outlook</h2>The company said it expects first quarter revenue for 2026 in the range of $28.5 million to $30 million, which was below Wall Street expectations of $31.5 million.&nbsp;Blend's first quarter 2026 guidance reflects certain assumptions and expectations related to U.S. aggregate industry mortgage originations. “Our first quarter 2026 market size expectation is 1.10 million to 1.20 million units. For the second quarter of 2026 we expect a sequential volume increase, in line with normal seasonal patterns. Our current expectation for the second quarter of 2026 is 1.50 to 1.60 million units,” the company said in its earnings release.&nbsp;"What excites me most going into 2026 is not just our growing roster of customers — it's what we're now able to offer them. Blend Autopilot, our new AI agent, is already live with large customers and is attacking the $11,000 cost-to-originate head-on,” said Nima Ghamsari, Co-founder and Head of Blend.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around BLND trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;Shares in the company have fallen nearly 46% year-to-date.&nbsp;

Blend Labs repurchased 5.1 million shares in the fourth quarter for more than $15 million, bringing the year-to-date total to $25 million.

Why Is Micro-Cap Stock Blend Labs Surging After Hours?

The company posted fourth quarter revenue of $32.4 million, an increase of 7% compared to the fourth quarter of 2024.

<ul class="summary-bullets"><li>The siRNA material will support the preclinical development of a therapeutic candidate for the treatment of a cardiovascular condition, the company said.</li><li>In January, Codexis tied up with Axolabs to evaluate its ECO Synthesis platform.</li><li>The firm is expected to post its Q4 results next week, with Wall Street expecting revenue to surge around 67% to $35.8 million.</li></ul>Shares of Codexis, Inc. (CDXS) gained 7% on Wednesday after the company announced an agreement with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis platform.Codexis, however, did not disclose the name of the firm.The siRNA material will support the preclinical development of a therapeutic candidate for the treatment of a cardiovascular condition. Codexis’ ECO Synthesis platform is built to enable scalable, high-fidelity production of complex siRNA therapies.As RNA-based medicines move beyond rare diseases into larger patient populations, manufacturing requirements are rising significantly. The company believes its enzymatic technology is well-positioned to meet this growing demand.&nbsp;“We are excited about this relationship as it represents an important entry point into what could become a high-volume opportunity,” said Alison Moore, President and Chief Executive Officer of Codexis.<h2 class="st-heading-2">Axolabs Partnership For ECO Synthesis Platform</h2>The news follows Codexis’ agreement earlier this year with Axolabs to evaluate its ECO Synthesis platform, a step that could lead to future licensing opportunities and wider adoption of the technology in RNA manufacturing.Kathleen Campau, Senior Director of Operations at Axolabs, had said that the technology could play a pivotal role in the future large-scale manufacturing of therapeutic oligonucleotides by enabling more sustainable and cost-effective production.The biotech firm is expected to post its fourth-quarter results next week, with Wall Street expecting revenue to surge around 67% to $35.8 million, according to Fiscal.ai data, while loss is expected to narrow to $0.04 per share.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/CDXS">CDXS</a> on Stocktwits turned ‘bullish’ from ‘neutral’ a day earlier, amid ‘high’ message volumes.One user believes the latest development adds “momentum and validation.”<stembedurl>https://stocktwits.com/Camille65/message/646560686</stembedurl>Another user noted they were neutral earlier but turned bullish on the stock after reading the announcement.<stembedurl>https://stocktwits.com/10xMoonstocks/message/646571515</stembedurl>The stock has been under heavy selling pressure this year, declining more than 36%Read also: &nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/crwv-stock-coreweave-perplexity-cloud-partnership/cZd9F11RI5u">CoreWeave Inks Deal With Perplexity – CRWV Stock Gains 6% Pre-Market, On Track To Arrest Post Earnings Slump</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artistic representation of a trending chart.

Why Did CDXS Stock Jump 7% Today?

The company tied up with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA using a proprietary ECO Synthesis platform.

<ul class="summary-bullets"><li>Aardvark voluntarily paused the HERO Phase 3 trial on Friday after a routine safety monitoring of a healthy volunteer found reversible cardiac effects.</li><li>Aardvark said it no longer expects to release HERO trial topline data in Q3 2026.</li><li>Stifel called the development a “surprise” and said that the “added uncertainty is hard to get comfortable with.”</li></ul>Shares of Aardvark Therapeutics (AARD) plummeted 4% in pre-market trading on Monday after a wave of bearish analyst downgrades following the company’s decision to pause its Phase 3 trial evaluating the treatment for hyperphagia in patients with Prader-Willi syndrome.If the pre-market levels hold after the opening bell, <a href="https://stocktwits.com/symbol/AARD">AARD shares</a> could fall to their lowest levels since Apr. 9, 2025.On Friday, Aardvark said it voluntarily paused the HERO Phase 3 and related extension trials after a routine safety monitoring of a healthy volunteer found reversible cardiac effects at doses above the target therapeutic level.Aardvark said it no longer expects to release HERO trial topline data in the third quarter (Q3) of 2026 and will instead provide updated guidance in the second quarter.<h2 class="st-heading-2">Analyst Expresses Skepticism About The New Uncertainty</h2>Stifel downgraded Aardvark Therapeutics to ‘Hold’ from ‘Buy’ and reduced its price target to $6 from $24, according to The Fly. This represents a 52% downside to Friday’s closing price of $12.5. The brokerage called the development a “surprise” and said that the “added uncertainty is hard to get comfortable with.” It is “very hard to build confidence in what the path forward may look like,” Stifel added.Morgan Stanley downgraded Aardvark Therapeutics to ‘Equal Weight’ from ‘Overweight’ and significantly slashed its price target to $7 from $29, according to The Fly. While the brokerage still sees potential for ARD-101, it lowered its rating due to near-term uncertainties.RBC Capital said that timelines are likely to be significantly delayed as the Aardvark works with the FDA on next steps, adding a “layer of uncertainty” around the program. The brokerage downgraded the stock to ‘Sector Perform’ from ‘Outperform’ and cut its price target to $6 from $18.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>While retail sentiment on Stocktwits remained ‘extremely bullish,’ amid ‘extremely high’ message volumes, chatter was largely ‘bearish’.<img src="https://news.stocktwits-cdn.com/AARD_jpg_eaa4fec962.webp" alt="AARD.jpg">One user said the suspension of the trial was “one of the worst news.”<stembedurl>https://stocktwits.com/focafoca99/message/646219667</stembedurl>Another user expects the stock to decline to $3.<stembedurl>https://stocktwits.com/jojoraizza/message/646210388</stembedurl>The stock has lost around 56% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/spy-falls-100-day-moving-average-oil-vix-middle-east-tensions/cZd33g2RIcH">SPY On Track To Fall Below 100-DMA For First Time In Nine Months – Retail Braces For Prolonged Volatility</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

S&P 500 Index trades listlessly ahead of Nvidia earnings. 

AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial

Aardvark Therapeutics shares saw brokerage downgrades after the company paused its Phase 3 trial to treat hyperphagia in patients with Prader-Willi syndrome.

<ul class="summary-bullets"><li>Aurinia stated that the revenue from the sales of LUPKYNIS for the treatment of active lupus nephritis rose 29% YoY in Q4 to $74.2 million and 25% YoY for the full year to $271 million.</li><li>LUPKYNIS is the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, the company said.</li><li>Overall, LUPKYNIS sales accounted for about 96% of the company’s total revenue in Q4 and for the full year 2025.</li></ul>Aurinia Pharmaceuticals Inc. (AUPH) shares gained nearly 4% in Thursday’s pre-market trade after the company posted a fourth-quarter (Q4) earnings and revenue beat.Aurinia reported adjusted earnings per share (EPS) of $1.53 on revenue of $77.1 million, while Wall Street analysts expected an adjusted EPS of $0.22 on revenue of $74.7 million, according to Koyfin data.However, the company’s 2026 revenue guidance fell short of Wall Street expectations. Aurinia guided for revenue in the range of $315 million and $325 million during the year, but the consensus estimate stood at $326.8 million.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/AUPH">Aurinia Pharmaceuticals</a> trended in the ‘bullish’ territory, with message volumes at ‘high’ levels. The stock was among the top three trending tickers on the platform at the time of writing.<h2 class="st-heading-2">Active Lupus Nephritis Therapy Sales Gain Momentum</h2>Aurinia stated that the revenue from the sales of LUPKYNIS for the treatment of active lupus nephritis rose 29% YoY in Q4 to $74.2 million. For the full year, LUPKYNIS sales stood at $271 million, rising 25% YoY.LUPKYNIS is the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, the company said.Overall, LUPKYNIS sales contributed to about 96% of the company’s total revenue in Q4 as well as the full year 2025.Aurinia also stated that the full-year revenue includes a $10 million milestone payment received by the company following the approval of LUPKYNIS by regulators in Japan.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>One user called Aurinia’s earnings and cash position “solid.”<stembedurl>https://stocktwits.com/VSTN/message/645950955</stembedurl>Another user called Aurinia’s numbers “excellent,” saying they’re excited for the company's long-term shareholders.<stembedurl>https://stocktwits.com/Ballerdad1/message/645950749</stembedurl><a href="https://stocktwits.com/symbol/AUPH">AUPH stock</a> is down 10% year-to-date, but up 80% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/celh-stock-soaring-today-celsius-q4-earnings-beat/cZTG9gDRIb8">CELH Stock Is Soaring Pre-Market Today — What Is Driving The Surge?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aurinia Pharmaceuticals logo is seen displayed on a smartphone screen

AUPH Stock Gains On Aurinia Pharma’s Q4 Beat, But 2026 Guidance Misses Estimates

Aurinia reported adjusted earnings per share of $1.53 on revenue of $77.1 million, while Wall Street analysts expected an adjusted EPS of $0.22 on revenue of $74.7 million, according to Koyfin data.

<ul class="summary-bullets"><li>Palvella said the study met its key secondary endpoint and all four additional secondary endpoints.</li><li>In the Phase 3 SELVA study, QTORIN rapamycin was generally well tolerated.&nbsp;</li><li>The company plans to submit an NDA to the U.S. FDA in the second half of 2026.</li></ul>Shares of Palvella Therapeutics Inc (PVLA) jumped nearly 37% on Tuesday, after the company reported positive topline results from its Phase 3 SELVA study, potentially paving the way for a FDA submission.&nbsp;The company said its lead candidate, QTORIN 3.9% rapamycin anhydrous gel, met its primary endpoint, showing a statistically significant improvement on the Microcystic Lymphatic Malformation Investigator Global Assessment scale.&nbsp;The study also met its key secondary endpoint and all four additional secondary endpoints, each demonstrating statistical significance in patients with microcystic lymphatic malformations (MLM), a rare vascular condition. MLM is a benign, fluid-filled cyst that can form under the skin, often on the neck or the head.<h2 class="st-heading-2">QTORIN Rapamycin Was Well Tolerated</h2>In the Phase 3 SELVA study, QTORIN rapamycin was generally well tolerated. Of the 50 patients who started treatment, 70% reported side effects, most of which were mild or moderate. Four serious adverse events were reported, but investigators said they were not related to the drug. The most common treatment-related issues were mild skin reactions at the application site.88% of the patients completed the 24-week study. Nearly all eligible participants chose to continue treatment in the extension phase.Based on these results, the company plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2026, with potential U.S. approval expected in the first half of 2027, the firm added.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ following the update, from ‘neutral’ a day earlier. Message volume on the platform was ‘extremely high’.<img src="https://news.stocktwits-cdn.com/PVLA_jpg_d1bfdadf88.webp" alt="PVLA.jpg">Year-to-date, the stock has gained around 16%&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did PVLA Stock Surge 37% Today?

The biotech company reported statistically significant Phase 3 data for QTORIN gel.

PVLA Stock Soars On Strong Phase 3 Results For Rare Vascular Disorder Treatment 

<ul class="summary-bullets"><li>The contract encompasses a broad range of work areas that allows for the rapid delivery of innovative capabilities to the warfighter with increased speed and agility, it said in a statement.&nbsp;</li><li>Participation in the SHIELD IDIQ contract provides a contractual framework through which IonQ may compete for future task orders, subject to agency requirements and competitive selection processes.&nbsp;</li><li>IonQ has a history of supporting U.S. government research and development initiatives, including work with agencies such as DARPA, the U.S. Air Force Research Laboratory.&nbsp;</li></ul>IonQ on Monday announced that it won a contract from the Missile Defense Agency’s Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) program, which has a ceiling&nbsp;worth up to $151 billion.At the time of writing stock was up 2%.&nbsp;The contract encompasses a broad range of work areas that allows for the rapid delivery of innovative capabilities to the warfighter with increased speed and agility, it said in a statement.&nbsp;IonQ has a history of supporting U.S. government research and development initiatives, including work with agencies such as DARPA, the U.S. Air Force Research Laboratory, and organizations across the national security community.<h2 class="st-heading-2">SHIELD IDIQ</h2>IonQ is among more than 2,400 companies eligible to compete for future task orders issued under the SHIELD IDIQ contract framework.Participation in the SHIELD IDIQ contract provides a contractual framework through which IonQ may compete for future task orders, subject to agency requirements and competitive selection processes.&nbsp;“IonQ brings together a broad set of quantum technologies and supporting capabilities that reflect years of investment across computing, networking, sensing, and security,” said Niccolo de Masi, Chairman and CEO of IonQ. “We look forward to continuing our work with U.S. government partners across a range of research, development, and innovation programs.”<h2 class="st-heading-2">Other Firms In The Program</h2>AST SpaceMobile Inc. (ASTS) in January announced that it has been awarded a contract for the Missile Defense Agency SHIELD program.AST SpaceMobile was selected as a lead contractor, granting the company the opportunity to compete for a variety of upcoming projects. These projects could encompass research, development, engineering, prototyping, and overseeing vital systems for the Missile Defense Agency that support U.S. national security interests.<h2 class="st-heading-2">How Did Stocktwits’ Users React?</h2>Retail sentiment around IONQ trended in ‘bearish’ territory amid ‘low’ message volume.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, a person holds a smartphone displaying the logo of IONQ Inc.

Why Is IonQ Stock Surging After-Hours?

IonQ is among more than 2,400 companies eligible to compete for future task orders issued under the SHIELD IDIQ contract framework.

Current Price	$316.69
Prev Close	$321.00
Open	$318.94
Dividend Yield	N/A
50-Day Moving Average	$336.62
Beta	N/A
Avg. Volume	441,232.70
PE Ratio	N/A

52-Week High	$355.34
52-Week Low	$219.19
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

IWO
iShares Russell 2000 Growth ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWO News

IWOiShares Russell 2000 Growth ETF